What is it about?

Heart failure is an impactful complication of type 2 diabetes mellitus. We developed and validated a risk score for hospitalization for heart failure in type 2 diabetes mellitus that incorporates 2 cardiovascular biomarkers (NT-proBNP and hsTnT) and prior history of heart failure. The risk score identifies patients at higher risk of hospitalization for heart failure who derive greater absolute treatment benefit from dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor.

Featured Image

Read the Original

This page is a summary of: A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes, Diabetes Care, September 2021, American Diabetes Association,
DOI: 10.2337/dc21-1170.
You can read the full text:

Read

Contributors

The following have contributed to this page